Intellia Therapeutics

NTLAsupplier

Intellia Therapeutics is a leading CRISPR gene-editing company developing in vivo therapies that edit genes directly inside the body. Its NTLA-2001 for transthyretin amyloidosis was the first in vivo CRISPR therapy to show clinical proof of concept in humans.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($0.15B)

Datos estáticos (cargando finanzas en tiempo real…)

Collaboration & License Revenue (70%)

Grants & Other (30%)

Composición de segmentos y clientes principales

Detalles del producto

NTLA-2002 (HAE Gene Editing)40%

In vivo CRISPR therapy for hereditary angioedema via liver-targeted gene knockout

NTLA-2001 (ATTR Gene Editing)35%

In vivo CRISPR therapy for transthyretin amyloidosis

Ex Vivo Cell Therapies15%

CRISPR-edited cell therapies for cancer and autoimmune disease

Relaciones en la Cadena de Suministro

Socios

Regeneron Pharmaceuticals

Co-development of ex vivo cell therapies

Impacto: Medium — Regeneron partnership for cell therapies

Competidores

Novo Nordisk

Rare blood disorder therapies

Impacto: Potential future competition

Pfizer Inc.

Gene therapy approaches

Impacto: Competing in genetic medicine pipeline

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Intellia Therapeutics impulsado por IA.

Información de la Empresa

Sede Central

Cambridge, Massachusetts, USA

Fundación

2014

Empleados

750+

Sitio Web

intelliatx.com

Estado del sector — 제약 / 바이오

Noticias del sector